Problem drug use the public health imperative: what some of the literature says

Substance Abuse Treatment, Prevention, and Policy

Gez Bevan¹ 

[1] University of Sunderland, Faculty of Applied Sciences, Chester Rd, Sunderland, SR1 3SD, UK

Others  :  838051
DOI  :  10.1186/1747-597X-4-21

 received in 2009-06-26, accepted in 2009-12-16,  发布年份 2009

【 摘 要 】

Background

With more than 200,000 problem drug users is contact with structured treatment services in England the public health imperative behind drug treatment is great. Problem drug use for many is a chronic and relapsing condition, where "cure" is often neither a reasonable or appropriate expectation and it can further be argued that in these circumstances problem drug use is no different from any number of chronic and enduring health conditions that are managed in the health care system and therefore should be conceptualised as such.

Discussion

A public health approach to drug treatment emphasises the need for drug users in or accessing treatment, to reduce their harmful drug use, reduce drug use related risks such as sepsis and overdose and stay alive for longer. However a public health perspective in relation to problem drug use isn't always either apparent or readily understood and to that end there is still a significant need to continue the arguments and debate that treatment and interventions for problem and dependent drug users need to extend beyond an individualistic approach. For the purposes of discussion in this article public and population health will be used interchangeably.

Summary

A recognition and acceptance that a public and population health approach to the management of problem drug users is sound public health policy also then requires a long term commitment in terms of staffing and resources where service delivery mirrors that of chronic condition management.

【 授权许可】

   
2009 Bevan; licensee BioMed Central Ltd.

【 参考文献 】

• [1]National Treatment Agency for Substance Misuse Numbers in Treatment, Drug Treatment Activity 2007/8 NTA
• [2]Newcombe R: The reduction of drug related harm: a conceptual framework for theory, practice and research. In The reduction of drug related harm. Edited by O'Hare PA, Newcombe R, Matthews A, Buning EC, Drucker E. London Routledge; 1992.
• [3]Ritter , Cameron : A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit. Drug & Alcohol Review 2006, 25(6):611-24.
• [4]International Harm Reduction Association: What is Harm Reduction? [http://www.ihra.net/Whatisharmreduction] webcite 2006.
• [5]Stimson G: Aids and injecting drug users in the UK 1987-1993, the policy response to an epidemic. Social Science and Medicine 1995, 41(5):699-716.
• [6]Judd A, Hickman M, McDonald T, Parry J, Stimson V, Hall A: Incidence of Hepatitis C virus and HIV among new injecting drug users in London: A prospective cohort study. British Medical Journal 2005, 330(7481):24-25.
• [7]Brown T, King A: Understanding the psychological effects of street drugs. Mind Publications; 2007.
• [8]National Treatment Agency for Substance Misuse: Models of Care for the treatment of drug misusers: Promoting quality, efficiency and effectiveness in drug misuse treatment services in England. National Treatment Agency; 2002.
• [9]WHO: Substance Abuse. [http://www.who.int/topics/substance_abuse/en/] webcite 2009.
• [10]Scott CK, Foss MA, Dennis ML: Pathways in the relapse-treatment-recovery cycle over 3 years. Journal of Substance Abuse Treatments 2005, 28(suppl 1):63-72.
• [11]Royal Pharmaceutical Society of Great Britain: Pharmacists and Methadone. Pharmacy Briefing 2005.
• [12]McIntosh J, McKeganey N: Addicts' narratives of recovery from drug use: constructing a non-addict identity. Social Science and Medicine 2000, 50(10):1501-10.
• [13]Leukefeld CG, Tims FM: Relapse and Recovery in drug abuse: research and practice. International Journal of Addiction 1989, 4(3):189-201.
• [14]Levy MS: Listening to our clients: The prevention of relapse. Journal of Psychoactive Drugs 2008, 40(2):167-172.
• [15]Scott CK, Dennis ML, Foss MA: Utilizing Recovery Management Checkups to shorten the cycle of relapse, treatment re-entry and recovery. Drug and Alcohol Dependency 2005, 78(3):325-38.
• [16]Termorshuzen F, Krol A, Prions M, Van Ameijden: Long term outcomes of chronic drug use; the Amsterdam cohort among drug users. American journal of Epidemiology 2005, 161(3):271-9.
• [17]Royal College of General Practitioners: Handbook for Primary Care organisations and other providers of face to face training. RCGP; 2004.
• [18]McEvoy P, Barnes P: Using the chronic care model to tackle depression among older adults who have long-term physical conditions. Journal of Psychiatric & Mental health Nursing 2007, 14(3):233-8.
• [19]Hung D, Rundall T, Tallia A, Cohen D, Crabtree B: Rethinking prevention in Primary Care: applying the Chronic Care Model to address health risk behaviours. The Millbank Quarterly 2007, 85(1):91.
• [20]Kugler C, Vlaminck H, Haverich A, Maes B: Non adherence with diet and fluid restrictions among adults having haemodialysis. Journal of Nursing Scholarship 2005, 37(1):25-9.
• [21]Maclean D, Lo R: the non-insulin dependent diabetic: success and failure of compliance Australian. Journal of Advanced Nursing 1998, 15(4):32-42.
• [22]Cramer JA: A systematic review of adherence with medication for diabetes. Diabetes Care 2004, 27(5):1218-1224.
• [23]Swaby P, Wilson E, Swaby S, Sue-Ho R, Pierre R: Chronic diseases management in the Jamaican setting: HOPE worldwide Jamaica's experience. Papua and New Guinea Medicine 2001, 44(3-4):171-5.
• [24]Bhattacharaya N, Biswas R, Das MK, Chatterjee PS: A study of the compliance of diabetes mellitus patients. Indian Journal of Public Health 2005, 49(1):34-5.
• [25]Bentley B, De Jong MJ, Moser DK, Peden : Factors related to non-adherence to a low salt diet recommendations in heart failure patients. European Journal of Cardio-Vascular 2005, 4(4):331-6.
• [26]Durose C, Holdworth M, Watson V, Prygrodzka : Knowledge of dietary restrictions and the medical consequences of non-compliance by patients on haemodialysis are not predictive of dietary compliance. Journal of the American Dietetics Association 2004, 104(1):41-42.
• [27]Zgibor JC, Simmons D: Barriers to blood glucose monitoring in a multiethnic community. Diabetes Care 2002, 25(10):1772-7.
• [28]Koch T, Jenkin P, Kralik D: Chronic Illness self management: locating the self. Journal of Advanced Nursing 2004, 48(5):484-92.
• [29]Karda P: Patient compliance with antibiotic treatments for respiratory tract infection. Journal of Antimicrobial Chemotherapy 2002, 49(6):897-903.
• [30]Sanson-Fisher R, Bowman J, Armstrong S: Factors affecting the non-adherence with antibiotics. Diagnosing Microbiological Infectious Diseases 1992, 15(4 Suppl):103-109.
• [31]Kardas P: Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. Journal of Antimicrobial Chemotherapy 2007, 59(3):531-6.
• [32]Laudet AB, Becker JB, White WL: Don't wanna go through that madness no more: quality of life satisfaction as predictor of sustained remission from illicit drug misuse. Substance Use & Misuse 2009, 44(2):227-52.
• [33]Appel PW, Ellison AA, Jansky HK, Oldak R: Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders. American Journal of Drug & Alcohol Abuse 2004, 30(1):129-53.
• [34]Meier PS, Barrowclough C, Donmall MC: The role of the therapeutic alliance in the treatment of substance misuse: a critical review of the literature. Addiction 2005, 100(3):304-16.
• [35]Sellman D: The 10 most important things known about addiction. Addiction 2009, in press.
• [36]Denning P: strategies for implementing harm reduction in treatment settings. Journal of Psychoactive Drugs 2001, 33(1):23-6.
• [37]Keen J, Oliver P, Rowse G, Mathers N: Does Methadone Maintenance treatment based on the new national guidelines work in a primary care setting? British Journal of General Practice 2003, 461-466.
• [38]Zhang Z, Friedmann PD, Gerstein DR: Does Retention Matter? Treatment duration and improvement in drug use. Addiction 2003, 98(5):673-84.
• [39]Stewart D, Gossop M, Marsden J: Reductions in non fatal overdose after drug treatment; results from the National Treatment Outcome Research Study (NTORS). Journal of Substance Abuse Treatments 2002, 22(1):1-9.
• [40]Gossop M, Marsden J, Stewart D, Treacy S: Changes and stability after treatment of drug misuse: 2 year outcomes from the National Treatment outcome Research Study (UK). Addictive Behaviour 2002, 27(2):155-66.
• [41]Gossop M, Marsden J, Stewart D, Kidd T: The National Treatment Outcome Research Study (NTORS) 4-5 year follow up result. Addiction 2003, 98(3):291-303.
• [42]Torrens M, Castillo C, Perez-Sola V: Retention in Methadone Maintenance programme. Drug and Alcohol Dependency 1996, 41(1):55-9.
• [43]D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bergagli AM: Retention in treatment of heroin users in Italy; the role of treatment type and of methadone maintenance dosage. Drug and Alcohol Dependency 1998, (2):167-71.
• [44]Mattick RP, Breen C, Kimber J, Davoli M: Methadone Maintenance therapy v no opioid replacement therapy for opioid dependence. [http:/ / mrw.interscience.wiley.com/ cochrane/ clsysrev/ articles/ CD002209/ pdf_fs.html] webciteCochrane Database of Systematic Reviews 2002, (3):CD002209.
• [45]Gerra G, Ferru M, Polidori E, Santoro G, Zaimovic A, Sterniere E: Long term methadone maintenance effectiveness: psychosocial and pharmacological variables. Journal of Substance Misuse Abuse treatment 2003, 25(1):1-8.
• [46]Brady TM, Salvucci S, Sverdlov LS, Male A, Kyeyune H, Sikali E, Desale S, Yu P: Methadone dosage and retention: an examination of the 60 mh/day threshold. Journal of Addictive Diseases 2005, 24(3):23-47.
• [47]VIllafranca SW, McKellar JD, Trafton JA, Humphreys K: Predictors of retention in methadone programmes: A signal detection analysis. Drug & Alcohol Dependence 2006, 83(3):218-24.
• [48]Joe GW, Simpson DD, Hubbard RL: treatment predictors of tenure in methadone maintenance. Journal of Substance Abuse 1991, 3(1):73-84.
• [49]Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH: Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. American Journal of Public Health 1995, 85(1):83-88.
• [50]Bell J, Chan J, Kuk A: Investigating the influence of treatment philosophy on outcomes of methadone maintenance. Addiction 1995, 90(6):823-30.
• [51]Strain EC, Bigelow GE, Liebson IA, Stitzer ML: Moderate v high does methadone in the treatment of opioid dependence: a randomized control trial. The Journal of the American Medical Association 1999, 281(11):1000-5.
• [52]Farre M, Mas A, Torrens M, Moreno V, Cami J: Retention and illicit opioid use during methadone maintenance interventions: a Meta analysis. Drug and Alcohol Dependence 2002, 65(3):283-90.
• [53]Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, Preston KL: Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Dependence 2009, 101(1-2):92-100.
• [54]Langendam MW, Van Brussel GH, Coutinho RA, Van Ameijden EJ: Methadone Maintenance and cessation of injecting drug use: results from the Amsterdam Cohort Study. Addiction 2000, 95(4):591-600.
• [55]Langendam MW, Van Brussel GH, Coutinho RA, Van Ameijden EJ: The impact of harm reduction based methadone maintenance treatment on mortality among heroin users. American Journal of Public Health 2001, 91(5):774-80.
• [56]Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L: A meta-analysis of retention in methadone maintenance by dose and dosing strategy. The American journal of drug and alcohol abuse 2009, 35(1):28-33.
• [57]Hunter G, Stimson G, Judd A, Jones S, Hickman M: Measuring injecting risk behaviour in the 2nd decade of harm reduction: A survey of injecting drug users in England. Addiction 2000, 95(9):1351-61.
• [58]Hope VD, Judd A, Hickman M, Sutton A, Stimson GV, Parry JV, Gill ON: HIV prevalence amongst injecting drug user in England and Wales1990-2003: evidence for increased transmission in recent years. AIDS 2005, 19(11):1207-14.
• [59]Bury K, Ross A, Van Teijlingen E, Porter A, Bath G: Lothian General Practitioners, HIV infection and drug misuse: epidemiology, experience and confidence 1988-1993. Health Bulletin (Edinb) 1996, 54(3):258-69.
• [60]Davies AG, Cormack RM, Richardson AM: Estimation of injecting drug users in the City of Edinburgh, Scotland and number infected with Immunodeficiency virus. International Journal of Epidemiology 1999, 28(1):117-21.
• [61]Seaman SR, Bird SM, Brettle RP: Historical HIV prevalence in Edinburgh prison: a database linkage study. Journal of Epidemiology and Biostatistics 2000, 5(4):245-250.
• [62]Parsons J, Hickman M, Turnball PJ, McSweeny T, Stimson GV, Judd A, Roberts K: Over a decade of syringe exchange: results from 1997 UK survey. Addiction 2002, (7):845-50.
• [63]Brettle RP, Bisset K, Burns S, Davidson J, Davidson SJ, Gray JM, Inglis JM, Lees JS, Mok J: Human immunodeficiency virus and drug misuse: the Edinburgh experience. British Medical Journal 1987, 295(6595):421-4.
• [64]Greenwood J: Creating a new drug service in Edinburgh. British medical journal 1990, 300(6724):587-9.
• [65]Stimson GV: "Harm reduction--coming of age": a local movement with global impact. International Journal of Drug Policy 2007, 18(2):67-9.
• [66]Mohsen AH, Murad S, Easterbrook PJ: Prevalence of hepatitis C in an ethnically diverse HIV-1 infected cohort in South London. HIV Medicine 2005, (3):206-15.
• [67]Pybus OG, Cochrane A, Holmes EC, Simmonds P: The hepatitis C virus epidemic infection among injecting drug users. Infection Genetics and Evolution 2005, 5(2):131-9.
• [68]Smyth BP, Keenan E, O'Connor JJ: Blood borne viral infection in Irish injecting drug users. Addiction 1998, 93(11):1649-56.
• [69]Das HK, Borkakoty BJ, Mahanta J, Medhi GK, Chelleng PK: Hepatitis C virus infection and risk behaviors among injection drug users of Nagaland. Indian Journal of Gastroenterology 2007, 26(5):253.
• [70]Chelleng PK, Borkakoty BJ, Chetia M, Das HK, Mahanta J: Risk of hepatitis C infection among injection drug users in Mizoram, India. The Indian Journal of Medical Research 2008, 128(5):640-6.
• [71]Shrestha SM, Shrestha DM, Gafney TE, Maharajan KG, Tsuda F, Okamoto H: Hepatitis B & C infection among drug users in Nepal. Tropical Gastroenterology 1996, 17(4):212-3.
• [72]Patrick DM, Buxton JA, Bingham M, Mathias RG: Public Health and Hepatitis C. Canadian Journal of Public Health 2000, 91(Suppl 1):s18-21.
• [73]Miller Cl, Johnston C, Spittal PM, Li K, Laliberte N, Montaner JS, Schechter MT: Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002, 36(3):737-42.
• [74]Dawson AJ: An ethical argument in favour of routine hepatitis B vaccination in very low-incidence countries. The Lancet Infectious Diseases 2005, 5(2):120-5.
• [75]Perrett K, Granerød J, Crowcroft N, Carlisle R: Changing epidemiology of hepatitis A: should we be doing more to vaccinate injecting drug. Communicable Disease & Public Health 2003, 6(2):97-100.
• [76]Bradshaw CS, Pierce LI, Tabrizi SN, Fairley CK, Garland SM: Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sample. Sexually Transmitted Infections 2005, 81(1):53-58.
• [77]McGregor J, Marks PJ, Hayward A, Bell Y, Slack RC: Factors influencing hepatitis B vaccine uptake in injecting drug users. Journal of Public Health 2003, 25(2):165-70.
• [78]Hunt DR, Saab S: Viral hepatitis in incarcerated adults: a medical and public health concern. The American Journal of Gastroenterology 2009, 104(4):1024-31.
• [79]Sherriff LC, Mayon-White RT: A survey of hepatitis C prevalence amongst the homeless community in Oxford. Journal of Public Health Medicine 2003, 25(4):358-61.
• [80]Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ: HIV and Hepatitis C co-infection within CAESAR study. HIV Medicine 2004, 5(3):174-9.
• [81]Robinson GM, Reynolds JN, Robinson BJ: hepatitis C prevalence and needle exchange/syringe sharing behaviours in recent onset injecting drug users. New Zealand Medical Journal 1995, 108(996):103-5.
• [82]Goldberg D, Mc Menamin J: The United Kingdom's hepatitis B immunistion strategy-where now? Communicable Disease and Public Health 1998, 1(2):79-83.
• [83]Edmunds WJ: Universal or selective immunisation against hepatitis B in United Kingdom? A review of recent cost-effectiveness studies. Communicable Disease and Public Health 1998, 1(4):221-228.
• [84]Hallett RL, Ngui SL, Meigh RE, Mutton KJ, Boxall EH, Teo CG: Widespread dissemination in England of a stable and persistent hepatitis B virus variant. Clinical Infectious Diseases 2004, 39(7):945-5.
• [85]Hope VD, Ncube F, Hickman M, Judd A, Parry JV: Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements. Journal of Viral Hepatitis 2007, 14(9):653-60.
• [86]Goudeau A: Epidemiology and eradication strategy for hepatitis B in Europe. The European Regional Study Group 1990, 8(Suppl):S113.
• [87]Raptopoulou M, Papatheodoridis G, Antoniou A, Ketikoglou J, Tzourmakliotis D, Vasiliadis T, Manolaki N, Nikolopoulou G, Manesis E, Pierroutsakos I: Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. Journal of Viral Hepatitis 2009, 16(3):195-20.
• [88]Jutavijittum P, Yousukh A, Samountry B, Samountry K, Ounavong A, Thammavong T, Keokhamphue J, Toriyama K: Seroprevalence of hepatitis B and C virus infections among Lao blood donors. The Southeast Asian journal of tropical medicine and public health 2007, 38(4):674.
• [89]Acharya SK, Madan K, Dattagupta S, Panda SK: Viral Hepatitis in India. National Medical Journal of India Viral hepatitis in India 2006, 19(4):203-17.
• [90]Zuckerman J, Langer B: Hepatitis B vaccination in a school age population: a feasibility study. Journal of Medical Virology 2005, 76(1):47-54.
• [91]Mele A, Stroffolini T, Zanetti AR: Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. Journal of Medical Virology 2002, 67(3):440-3.
• [92]Gonzales R, Glik D, Prelip M, Bourque L, Yuen J, Ang A, Jones M: Risk perceptions and behavioural intentions for Hepatitis B: how young people fare. Health Education Research 2006, 21(5):654-656.
• [93]Haldar A, Sarkar A, Dasgupta U: Perception of general population about hepatitis B: a cross-sectional study. Journal of Communicable Diseases 2005, 37(2):115-19.
• [94]Schenkel K, Radun D, Bremer V, Bocter N, Hamouda O: Viral hepatitis in Germany: poor vaccination coverage and little knowledge about transmission in target groups. BioMed Central Public Health 2008, 8:132.
• [95]Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J: Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. British Medical Journal 1999, 319(7205):290-1.
• [96]Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A: Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. New Zealand Medical Journal 2001, 114(1136):324.
• [97]Zanis DA, Woody GE: One year mortality rates following methadone treatment discharge. Drug and Alcohol Dependence 1998, 52(3):257-60.
• [98]Webb L, Oyefeso , Schifano F, Cheeta S, Pollard M, Ghodse AH: Cause and manner of death in drug related fatality: an analysis of drug related deaths recorded by coroners in England and Wales in 2000. Drug and Alcohol Dependence 2003, 72(1):67-74.
• [99]Preti A, Miotto P, De Coppi M: Deaths by unintentional illicit drug overdose in Italy 1984-2000. Drug and Alcohol Dependence 2002, 66:275-282.
• [100]Hickman M, Carnwath Z, Madden P, Farrell , Rooney C, Ashcroft R, Judd A, Stimson C: Drug related mortality and fatal overdose risk; pilot cohort study of heroin users recruited from specialist drug treatment sites in London. Journal of Urban Health 2003, 80(2):274-87.
• [101]Hickman M, Madden P, Henry J, Baker A, Wallace C, Wakefield J, Stimson C, Elliott P: Trends in drug overdose deaths in England and Wales 1993-98: methadone does not kill more people than heroin. Addiction 2003, 98(4):419-25.
• [102]Quaglio G, Talamini G, Lechi A, Venturini L, Lugoboni F, Mezzelani P, Gruppo Intersert di Collaborazione Scientifica: Study of 2708 heroin related deaths in north eastern Italy 1985-98 to establish the main cause of death. Addiction 2001, 96(8):1127-37.
• [103]Gronblahd L, Ohlund LS, Gunne LM: Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatrica Scandinavica 1990, 82(3):223-7.
• [104]Davoli M, Perucci CA, Forastiere F, Doyal P, Rapiti E, Zaccarelli M: Risk factors for overdose mortality: a case control study within a cohort of intravenous drug users. International Journal of Epidemiology 1993, 22(2):273-277.
• [105]Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG: Methadone Maintenance and addicts' risk of fatal heroin overdose. Substance Use & Misuse 1996, 31(2):177-96.
• [106]Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia De Olalla P, de la Fuente L: Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. Addiction 2005, 100(7):981-9.
• [107]Darke S, Williamson A, Ross J, Teesson M: Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug & Alcohol Review 2005, 24(5):425-32.